Department of Rheumatology and Immunology, Tongren Hospital, Shanghai JiaoTong University School of Medicine, No. 1111 Xianxia Road, Changning District, Shanghai, 200336, China.
BMC Ophthalmol. 2023 May 12;23(1):212. doi: 10.1186/s12886-023-02966-6.
Cogan's syndrome (CS) is a rare autoimmune disorder characterized by non-syphilitic interstitial keratitis (IK) and Menière-like cochlear vestibular symptoms, which may also have systemic effects. Corticosteroids are first-line treatment. DMARDs and biologics have been used to treat ocular and systemic symptoms of CS.
This is a case of a 35-year-old female who reported hearing loss, eye redness and photophobia. Her condition progressed to a sudden sensorineural hearing loss, tinnitus, and constant vertigo accompanied by cephalea. CS was diagnosed after excluding other diseases. The patient still developed bilateral sensorineural hearing loss after receiving hormone, methotrexate, cyclophosphamide, and a variety of biological agents. Joint symptoms were relieved after treatment with a JAK inhibitor (tofacitinib), and hearing did not deteriorate further.
CS should be involved in the differential diagnosis of keratitis. Early identification and intervention of this autoimmune disease can minimize disability and irreversible damage.
Cogan 综合征(CS)是一种罕见的自身免疫性疾病,其特征为非梅毒性间质性角膜炎(IK)和梅尼埃样耳蜗前庭症状,也可能有全身影响。皮质类固醇是一线治疗药物。DMARDs 和生物制剂已被用于治疗 CS 的眼部和全身症状。
这是一位 35 岁女性,她报告有听力损失、眼红和畏光。她的病情进展为突发性感音神经性听力损失、耳鸣和持续眩晕,并伴有头痛。排除其他疾病后诊断为 CS。患者在接受激素、甲氨蝶呤、环磷酰胺和多种生物制剂治疗后仍出现双侧感音神经性听力损失。用 JAK 抑制剂(托法替尼)治疗后关节症状缓解,听力未进一步恶化。
CS 应纳入角膜炎的鉴别诊断。早期识别和干预这种自身免疫性疾病可以最大限度地减少残疾和不可逆转的损害。